FAIR VALUE MEASUREMENTS

6 Months Ended

Jan. 31, 2026

NOTE 5: FAIR VALUE MEASUREMENTS

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of January 31, 2026 and July 31, 2025:

	Fair Value Measurements at
	January 31, 2026						July 31, 2025
	Level 1		Level 2		Total		Level 1		Level 2		Total
Financial Assets:
Cash and cash equivalents		29,903,628		-		29,903,628		10,493,808		-		10,493,808
Short-term investments		-		-		-		7,372,473		-		7,372,473
Total assets measured at fair value	$	29,903,628	$	-	$	29,903,628	$	17,866,281	$	-	$	17,866,281

Financial liabilities:
Warrants liability		38,578		156,518		195,096		151,586		186,086		337,672

Total liabilities measured at fair value	$	38,578	$	156,518	$	195,096	$	151,586	$	186,086	$	337,672

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

NOTE 5: FAIR VALUE MEASUREMENTS (Cont.)

We classify our cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets.

As of January 31, 2026, the Company did not hold any short-term investments. As of July 31, 2025, the Company held Level 1 short-term investments measured using quoted prices in active markets, with coupon rates ranging from 3% to 5.51%.

The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.